Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients
- 7 January 2003
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 20 (1) , 76-79
- https://doi.org/10.1046/j.1464-5491.2003.00848.x
Abstract
Aims Despite high‐dose s.c. insulin therapy, some Type 2 diabetes mellitus (DM) patients remain in poor metabolic control. We investigated whether a period of euglycaemia using i.v. insulin, followed by continuous subcutaneous insulin infusion (CSII), would ameliorate the deleterious effects of hyperglycaemia on insulin sensitivity and result in sustained, improved metabolic control. Methods In a prospective observational study, eight Type 2 DM patients with severe insulin resistance (insulin dose 1.92 ± 0.66 U/kg per day (mean ±sd)), in poor metabolic control (HbA1c 12.0 ± 1.7%), were treated with i.v. insulin for 31 ± 10 days aimed at euglycaemia, followed by CSII therapy for 12 months, using insulin lispro. Before and after 28 ± 6 days of i.v. insulin treatment, insulin sensitivity was measured by a hyperinsulinaemic euglycaemic clamp. Results Euglycaemia was reached after 12 ± 6 days of i.v. insulin treatment. Subsequently, the i.v. insulin dose required to maintain euglycaemia decreased from 1.7 ± 0.9 to 1.1 ± 0.6 U/kg per day (P < 0.005). Whole body glucose uptake increased from 12.7 ± 5.7 to 22.4 ± 8.8 µmol/kg per min (P < 0.0005). HbA1c decreased to 8.9 ± 1.2% after 28 ± 6 days, to 7.1 ± 0.6% after 6 months and to 8.3 ± 1.4% after 12 months (P < 0.001 vs. pretreatment, for all). Lipid profile improved and plasminogen activator inhibitor type 1 levels decreased significantly. Mean body weight did not change. Conclusions In Type 2 diabetic patients, who are poorly controlled despite high‐dose s.c. insulin treatment, a period of 2 weeks of euglycaemia achieved by i.v. insulin reverses hyperglycaemia‐induced insulin resistance and substantially improves metabolic control. Subsequent CSII treatment, using insulin analogues, appears to maintain improved metabolic control for at least 1 year. This approach is promising but needs further evaluation.Keywords
This publication has 16 references indexed in Scilit:
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999
- Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes MellitusNew England Journal of Medicine, 1998
- Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion and Conventional Insulin Therapy in Type II Diabetic Patients Poorly Controlled With SulfonylureasDiabetes Care, 1991
- One month's insulin treatment of type II diabetes: The early and medium-term effects following insulin withdrawalMetabolism, 1986
- Effects of Weight Loss on Mechanisms of Hyperglycemia in Obese Non-Insulin-Dependent Diabetes MellitusDiabetes, 1986
- The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes MellitusDiabetes, 1985
- Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin WithdrawalDiabetes, 1984
- The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic SubjectsDiabetes, 1984
- Differential effects of insulin therapy on hepatic and peripheral insulin sensitivity in Type 2 (non-insulin-dependent) diabetesDiabetologia, 1982
- Improvement of Insulin Secretion but Not Insulin Resistance after Short Term Control of Plasma Glucose in Obese Type II Diabetics*Journal of Clinical Endocrinology & Metabolism, 1982